Market Alert: Trump-Xi APEC Summit a Critical Test for Global Trade Stability

CSL Limited 2025 Annual General Meeting Summary.

Oct 28, 2025

CSL Limited (ASX: CSL) convened its 2025 Annual General Meeting in Melbourne, highlighting operational progress, financial achievements, and long-term objectives. The company posted revenue of US$15.6 billion, up 5%, and a net profit of US$3 billion, representing a 17% rise. Chair Brian McNamee emphasized the firm’s focus on streamlining operations, aiming to achieve over US$500 million in yearly pre-tax cost efficiencies by FY2028. CEO Paul McKenzie discussed the solid performance of CSL Behring and Vifor, while acknowledging short-term challenges in the U.S. flu vaccine segment and pricing pressures in China.

Despite near-term difficulties, CSL remains optimistic about sustainable growth, backed by strong cash generation, enhanced R&D productivity, and continued efficiency improvements. The planned separation of CSL Seqirus has been delayed until market conditions improve to protect shareholder value. The meeting also included leadership updates and fresh Board appointments to reinforce corporate governance and strategic alignment.

 

 

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com